Kornimate/medical-research-clean huggingface dataset:
the impact of virtual reality and kaleidoscope in children during vaccination

Conditions: Pain; Pediatric Patient; Fear; Virtual Reality; Nursing Caries

Summary: this study was designed to examine the effects of using virtual reality and kaleidoscope during routine vaccination in children aged 48 months on pain, fear, and anxiety. children aged 48 months who were to receive the measles-mumps-rubella vaccine were randomized into three groups. accordingly, the study sample consisted of a virtual reality group with 42 children, a kaleidoscope group with 42 children, and a control group with 42 children, totaling 126 children. fear and pain were evaluated by both the researcher and the child before and after the procedure. anxiety was assessed by the child after the procedure. the wong baker faces pain rating scale was used for pain, the children's fear scale for fear, and the child anxiety scale-state version for anxiety.


Eligibility criteria:
inclusion criteria: * being 48 months * being conscious (with the ability to communicate). exclusion criteria: * having a physical and psychological condition that prevents them from wearing glasses to view vr; * having a visual problem * having mental or physical disabilities * taking any analgesics, sedatives, or anticonvulsants in the past 24 hours * having chronic or life-threatening disease * refusing the vr or kaleidoscope intervention during vaccine injection.
assessment of functional capacity and inflammatory markers in women with heart failure with preserved ejection fraction

Conditions: Heart Failure, Diastolic; Coronary Artery Disease; Inflammation

Summary: this study assesses the impact of diastolic heart failure on exercise capacity in women who have a previous coronary condition. all the participants will go through the same evaluation.

it is well established that systolic heart failure impacts exercise capacity and quality of life, diastolic heart failure however, is not well documented as a condition that reduces physical performance. to confirm that patients have a diastolic disfunction an echocardiography will be performed, this will also yield the left ventricle ejection fraction to confirm the preserved ejection fraction heart failure diagnostics. exercise capacity will be assessed using the distance walked on the six-minute walking test, performed on a 30m corridor. pulmonary function will be assessed with spirometry and values of forced vital capacity and forced expired volume in one second will be recorded and compared to the age-predicted values. respiratory strength will be determined by maximal pressure achieved on a respiratory manometer. peripheral muscular strength will be assessed with a handheld dynamometer. knee extension strength of the dominant leg will be recorded. an echocardiography will be performed to assess systolic and diastolic function and ejection fraction. heart autonomic function will be evaluated using a heart rate monitor and a computer software to identify the sympathovagal balance.

Eligibility criteria:
inclusion criteria: * women; * aged between 35 and 70 years; * coronary artery disease proven by coronary angiography; * diastolic heart failure confirmed by recent echocardiography (6 months); * left ventricle ejection fraction of greater than 50%; * absence of acute or chronic pulmonary disease; * patient clinically compensated; * consent form signed for participation in the research exclusion criteria: * inability to perform spirometry; * presence of acute or chronic pulmonary disease; * chronic inflammatory disease, kidney or liver disease; * patients using corticosteroids, aspirin or other nonsteroidal anti-inflammatory; * clinical or laboratory evidence of infection; * morbid obesity; * hemodynamic instability at the time of spirometry; * patient's or legal guardian request to leave at any time of the study.
the nanostrand clinical study

Conditions: Disc Degeneration;Cervical

Summary: a prospective, multi-center, randomized, self-controlled, single-blinded, clinical study evaluating the nanometalene implant as compared to the peek and allograft implants in acdf for the treatment of cervical degenerative disc disease (ddd).

peek: polyetheretherketone acdf: anterior cervical discectomy and fusion

Eligibility criteria:
inclusion criteria: * cervical degenerative disc disease * requires primary spinal fusion from c3-c7 * minimum of 6 weeks of non-operative treatment * signed informed consent form exclusion criteria: * uncontrolled type i or ii diabetes mellitus * morbid obesity * documented history of alcohol or drug abuse * fever or leukocytosis * current systemic infection * active malignancy and/or current chemotherapy * known history of osteoporosis * prior fusion or total disc replacement at the operative level or an adjacent level * infection of the operative site * use of implants from other systems * pregnancy * participation in another research study
the value of vocs analysis in exhaled breath for pulmonary benign and malignant lesion diagnosis

Conditions: Lung Neoplasm; Lung Disease

Summary: the purpose of this study is to analysis the volatile organic gases(vocs) in exhaled breath of pulmonary lesion patients and healthy controls, in order to find the difference of composition and concentration among groups.

collect the exhaled gas in pulmonary lesion patients and healthy controls, using proton transfer reaction mass spectrometry to analysis the different composition and concentration of vocs, to find the biomarker gases of distinguishing benign and malignant lesion of lung among different groups， and try to build a diagnostic model for lung lesion.

Eligibility criteria:
inclusion criteria: * cohort 1 : inclusion criteria: patients newly diagnosed with primary lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy. age ≥ 18 years * cohort 2： inclusion criteria： patients diagnosed with pulmonary benign lesion by tissue biopsy or other examination. age ≥ 18 years exclusion criteria: patients who have more than one type of carcinoma patients diagnosed type 2 diabetes mellitus patients diagnosed chronic renal failure patients diagnosed upper digestive tract ulcer patients who reject to sign the informed consent from * cohort 3： healthy controls volunteers without diagnosed lung diseases and pulmonary symptoms.

Keywords: pulmonary lesion volatile organic compositions(vocs)
neuromark randomized controlled trial

Conditions: Chronic Rhinitis

Summary: the neuromark rct study is a prospective, multicenter, randomized, sham-controlled, single-blinded, superiority trial.


Eligibility criteria:
inclusion criteria: participant must: 1. be ≥18 years of age. 2. have been experiencing rhinitis symptoms for a minimum of 6 months. 3. have moderate to severe symptoms of runny nose (individual rtnss symptom rating of 2 or 3), mild to severe symptoms of nasal congestion (individual rtnss symptom rating of 1,2, or 3), and a minimum total score of 5 (out of 12) at baseline. 4. be an appropriate candidate for bilateral neuromark device treatment performed under local anesthesia. 5. be willing and able to comply with all study elements, as indicated by written informed consent. primary exclusion criteria: participant must not: 1. have clinically significant anatomic obstruction that in the investigator's opinion limit access to the posterior nose, including but not limited to severe septal deviation or perforation, nasal polyps, and/or sinonasal tumor. 2. have had previous sinus or nasal surgery within 6 months of study enrollment. 3. have previously undergone rf, cryotherapy, or other surgical interventions for rhinitis. 4. have rhinitis symptoms that are due to seasonal allergies only.
autologous nanofat grafting by injection versus with microneedling in post-burn and traumatic atrophic scars

Conditions: Scars

Summary: this study aims to evaluate the efficiency autologous nanofat injection versus autologous nanofat delivered by microneedling in management of post burn atrophic and traumatic scars.


Eligibility criteria:
inclusion criteria: * 1. males and females between 18-60 years old. 2. post-burn or traumatic atrophic scar \> 6 months duration (16). 3. patients not receiving any treatments for the scar within the past 3 months. exclusion criteria: * 1. patients with contractures, hypertrophic and keloid scars. 2. patients with history of bleeding disorders or coagulopathy, or on anticoagulant therpy. 3. diabetes and other systemic diseases that may be complicated by the procedure. 4. pregnant and lactating females. 5. bmi less than 18.5 6. patients with scars at the donor site
spanish validation and cross-cultural adaptation of the qor-15e

Conditions: Humans; Reproducibility of Results; Cross-Cultural Comparison; Surveys and Questionnaires; Postoperative Period; Anesthetics; Perception

Summary: the satisfactory recovery of the patient after a surgery with an anesthetic request is very important for a quality and excellence assistance. the quality of recovery questionnaire qor-15 was validated by their authors in 2013 with the study titled development and psychometric evaluation of a postoperative quality of recovery score: the qor-15. this questionnaire allows a comprehensive assessment by associating the physiological parameters until then assessed with the subjective personal perception of the patient of his state of health. with the consent of its original author, this study is carried out to validate the questionnaire in spanish and adapted to our environment.


Eligibility criteria:
inclusion criteria: * patients over 18 years old. * comprehensive and sign informed consent. * knows and understands the spanish language. * undergo a scheduled surgical intervention under any type of anesthetic procedure from the specialties of general surgery, urology and gynecology. * score \> 26 points in the mini mental state examination (mmse) test. exclusion criteria: * patients under 18 years old. * not having signed the informed consent. * not knowing or understanding the spanish language. * surgical intervention from other specialties than general surgery, urology and gynecology. * score \< 27 points in the mini mental state examination (mmse) test.

Keywords: quality recovery anesthesia validation adaptation spanish
identification of biomarkers of janus kinase inhibitor therapy in patients with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this study aims to provide new mechanistic insights into the molecular determinants of response or nonresponse to janus kinase inhibitor therapy and the biological heterogeneity that exists in ulcerative colitis. this study will include patients who are initiating janus kinase inhibitor therapy according to standard of care. this study consists of: * part 1: 8 or 10 week induction therapy followed by an 8-week maintenance therapy * part 2: patients who continue janus kinas inhibitor therapy after part 1 will be followed further for a total of 2 years, or until discontinuation of janus kinase inhibitor therapy (whichever is first)


Eligibility criteria:
inclusion criteria: 1.18 years of age or older. 2.male or nonpregnant, nonlactating females. 3.diagnosis of ulcerative colitis for at least 3 months prior to screening. 4.moderately to severely active ulcerative colitis (total mayo clinic score ≥ 6), with objective evidence of inflammation defined by a mayo endoscopic subscore (mes) ≥ 2 and disease extending \> 15 cm from the anal verge. 5.physician plans to administer janus kinase inhibitor for at least 8 weeks of induction therapy as part of standard of care (soc). 6.documentation of a negative test result for latent tuberculosis within the last 12 months, or according to routine clinical practice. 7.able to participate fully in all aspects of this clinical trial, including collection of tissue biopsies. 8.written informed consent must be obtained and documented. exclusion criteria: 1. diagnosis of crohn's disease or indeterminate colitis. 2. an active, serious infection, including localized infections. 3. concomitant administration of biological therapies for ulcerative colitis or potent immunosuppressants, such as azathioprine and cyclosporine. subjects with previous exposure to these treatments should undergo an appropriate washout period according to local practice prior to starting janus kinase inhibitor, in keeping with routine clinical practice. 4. hematology laboratory (e.g., absolute lymphocyte count, absolute neutrophil count, and hemoglobin that contraindicate the product label. 5. interval between live vaccinations and initiation of tofacitinib therapy should be in accordance with current vaccination guidelines regarding immunosuppressive agents. 6. serious underlying disease other than ulcerative colitis that in the opinion of the investigator may interfere with the subject's ability to participate fully in the study.
climacteric clinical trial : the use of complementary therapy and hormonal replacement

Conditions: Climacteric

Summary: the alternative and complementary therapies are being gradually included in the brazilian health unique system (sus), as it is foreseen in the national politics of integrative and complementary practices in brazil . however, though this thematic is also included in the national agenda of research priorities concerning health, published studies concerning this matter are quite scarce. the world health organization (who) indicated that it is a big challenge to effect the following studies: cost-effectiveness, as well as safety, efficiency and the quality of such practices. who also pointed out the clinical situations where they could be applied and that is why this investigation we are undertaken is fully justified. annoying signs and symptoms which come along with the climacteric period, especially anxiety, insomnia and hot flushes, change women´s life quality and their affective, social and business relationships as well. consequently, this can generate sadness, depression and isolation. many women cannot undergo hormonal replacement, for several reasons: or they have some illnesses which reject hormones, or due to hypersensitiveness reactions or even economical difficulties. also, the cost-effectiveness ratio between conventional therapy of hormonal replacement and complementary therapies which compose this study are not known yet . the complementary therapies proposed in this study concern non-invasive methods, of low cost, which justify being researched in order to verify the potential of those annoying signs alleviation.


Eligibility criteria:
inclusion criteria: * female * recruited and registered in local of the study * they should present the signs and symptoms checked - insomnia, anxiety and hot flushes, they felt at the beginning of the climacteric * they should not be under hormonal replacement or even should have stopped their use more than 90 days exclusion criteria: * women who undergo a hysterectomy surgery * women using hormonal therapy

Keywords: climacteric complementary therapy hormonal replacement therapy
streamlined resin y90 radiation segmentectomy for small hcc

Conditions: Hepatocellular Carcinoma (HCC)

Summary: this single-arm feasibility study evaluating the safety and efficacy of streamlining yttrium-90 (y90) radioembolization workflow for patients with small hepatocellular carcinoma (\&lt;5cm) that have no aggressive features on baseline imaging. this study aims to recruit n=30 patients prospectively and consolidate the current workflow of 2 days of procedures (1st-day mapping angiography followed by nuclear medicine hepatic lung shunt fraction (lsf) calculation using tc99-maa planar and spect/ct, and 2nd-day y90 radioembolization followed by nuclear medicine y90 spect/ct) into 1-day procedure. several studies have shown that hepatic lsf for hcc tumors smaller than 5cm in the absence of macrovascular invasion and portosystemic shunt placement is invariably \&lt;10%. therefore, the lsf calculation can be safely omitted from the complex workflow of these patients. this study aims to illustrate that this can be done safely and efficaciously to reduce unnecessary patient travel and healthcare resource utilization. overall, a total of 30 patients will be included in the study.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * has focal hepatocellular carcinoma and is deemed to benefit from yttrium-90 radioembolization by the institutional multidisciplinary tumor board exclusion criteria: * all subjects meeting any of the exclusion criteria at baseline will be excluded from study participation. * the presence of trans-jugular intrahepatic portosystemic shunt * total bilirubin level \&gt; 3.0 mg/dl * serum albumin level \&lt; 2.5 g/dl * aspartate and alanine aminotransferase levels no greater than five times the normal level * life expectancy \&lt; 12 weeks * eastern cooperative oncology group performance status \&gt; 2 * patients with chronic lung disease requiring supplemental oxygen at baseline or baseline spo2 of \&lt;92% * patients that have tumors with central anatomical locations close the hepatic hilum or caudate lobe. * patients with macrovascular invasion on baseline imaging * known hypersensitivity to iodinated contrast agents or to any component of iodinated contrast agents refractory to standard medications (antihistamines, steroids) * impaired kidney function (glomerular filtration rate \&lt; 30 as approximated using serum creatinine levels) unless anuric and on dialysis. * any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine β-hcg results, obtained within 48 hours prior to the treatment or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of 1 year without menses)

Keywords: radioembolization yttrium-90 workflow
bovine colostrum for prophylaxis against recurrent urinary tract infection in children

Conditions: Urinary Tract Infections; Recurrent; Child; Prevention & Control; Infections; Urologic Diseases; Communicable Diseases

Summary: prebiotics as bovine colostrum are considered as a valuable supplement in the prevention of upper respiratory tract infections, gastrointestinal tract infections and neonatal sepsis. it contains many bioactive substances, such as immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, and other growth factors.there is a lack of research on the use of prebiotics for prophylaxis against recurrent urinary tract infection (uti) in children.in this era of increasing bacterial resistance to antimicrobial therapy, bovine colostrum can offer an approach for prophylaxis against uti in these patients.we aim at this trial to evaluate the efficacy and safety of bovine colostrum as a prebiotic for prophylaxis against recurrent urinary tract infection in children.

this prospective,randomized, placebo-controlled pilot study will enroll a total of sixty children diagnosed with recurrent uti and following up in pediatric nephrology clinic at children's hospital at ain shams university. participants' parents will sign an informed consent statement prior to inclusion in the study. children fulfilling the eligibility criteria, whether they are already on antibiotic prophylaxis for uti or not, will be randomly assigned (1:1), using a computer-generated list into one of two groups: experimental group receiving oral bovine colostrum sachets daily for 1 month (n=30)\& control group receiving oral placebo sachets daily for the same duration(n=30). * patient demographics, clinical symptoms suggestive of uti, medication history, any risk factors for uti, and clinical examination will be obtained at baseline.these will be followed up monthly for 6 months after the beginning of the study either during clinic visits or via telephone calls. * urine analysis (ua) will be done at base line, and monthly for 6 months. however if symptoms suggestive of uti, ua will be requested. * urine culture at base line and with the appearance of symptoms or presence of pyuria in the urine analysis defined by \> 10 wbc /hpf.

Eligibility criteria:
inclusion criteria: * documented recurrent uti proven by positive urine culture. recurrent uti will be defined according to nice guidelines as any of the following: 1. 2 or more episodes of uti with acute pyelonephritis. 2. 1 episode of uti with acute pyelonephritis plus 1 or more episode of uti with cystitis. 3. 3 or more episodes of uti with cystitis. exclusion criteria: 1. allergy or hypersensitivity to the prescribed prebiotic. 2. presence of any endo-urinary device (ureteral stent). 3. presence of urinary stones

Keywords: bovine colostrum
fat perception in humans (09-0873)

Conditions: Obesity

Summary: there are many substances naturally present in the mouth that may help us taste fat in food. two of these substances (lipases and cd36) will be examined in this study. the presence of fat in food increases food tastiness, therefore people often over-eat high-fat foods and gain weight. the purpose of this study is to determine if blocking lipases and some genetic variations in the cd36 gene will make fatty food less tasty so that people eat less. our hypothesis is that orlistat and a particular gene will increase one's ability to detect fat.

1. determine the effect of lipolysis inhibition in oral cavity on orosensory detection of fat in humans. hypothesis: orally applied orlistat will increase detection thresholds of tags but not ffa in humans. to test this hypothesis we will measure triolein (a tag) and oleic acid (a ffa) taste detection thresholds with a three-alternative forced-choice (3-afc) ascending concentration method under two conditions (orlistat day vs. control day). to control for olfactory input, subjects will be assessed wearing noseclips. 2. determine the effect of cd36 variants on fat taste perception in humans. hypothesis: snps that associate with reduced cd36 expression will be associated with higher ffa and tag detection thresholds to test this hypothesis we will measure triolein and oleic acid taste detection thresholds in subjects who carry of the common cd36 e-snp rs1761667 (i.e. a snp that significantly reduces cd36 level and has a minor allele frequency of 38-48%). we expect subjects who are at least heterozygous for the expression reducing allele to have higher triolein and oleic acid taste detection thresholds compared to non-carrier subjects.

Eligibility criteria:
inclusion criteria: * body mass index greater than 30 kg/m² exclusion criteria: * smokers or who quit smoking less than six months ago * pregnancy * breastfeeding * diabetes * taking medications that might affect taste perception * previous malabsorptive or restrictive intestinal surgery

Keywords: obesity orlistat taste perception